Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma

Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma

Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma. Website: https://www.onclive.com Twitter:   / onclive   Facebook:   / onclive   LinkedIn:   / onclive